Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Cristina Soria, Lola Prieto, Esther Lázaro & Amalia Ubeda. (2023) Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain. Patient Preference and Adherence 17, pages 679-688.
Read now
Read now
Ramón Morillo Verdugo, Esther Ramírez Herráiz, Raquel Fernández-Del Olmo, Montserrat Roig Bonet & María Valdivia García. (2019) Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain. Patient Preference and Adherence 13, pages 261-272.
Read now
Read now
Dirk Deleu, Boulenouar Mesraoua, Beatriz Canibaño, Gayane Melikyan, Hassan Al Hail, Lubna El-Sheikh, Musab Ali, Hassan Al Hussein, Faiza Ibrahim & Yolande Hanssens. (2019) Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview. Current Medical Research and Opinion 35:2, pages 249-260.
Read now
Read now
Aleksandra Kołtuniuk & Joanna Rosińczuk. (2018) Adherence to disease-modifying therapies in patients with multiple sclerosis. Patient Preference and Adherence 12, pages 1557-1566.
Read now
Read now
Marieke Krol, Gert de Voer & Ulrike Osowski. (2017) Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. Patient Preference and Adherence 11, pages 1189-1196.
Read now
Read now
Michael Munsell, Molly Frean, Joseph Menzin & Amy L Phillips. (2017) An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Preference and Adherence 11, pages 55-62.
Read now
Read now
Frank R. Ernst, Peri Barr, Riad Elmor & Schiffon L. Wong. (2017) Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Current Medical Research and Opinion 33:12, pages 2099-2106.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza & Márcio Machado. (2017) Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies. Current Medical Research and Opinion 33:3, pages 579-593.
Read now
Read now
Leo H Visser, Marco A Heerings, Peter J Jongen & Karin van der Hiele. (2016) Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment. Patient Preference and Adherence 10, pages 659-667.
Read now
Read now
Damiano Paolicelli, Eleonora Cocco, Valentina Di Lecce, Vita Direnzo, Lucia Moiola, Roberta Lanzillo, Paola Perini, Simona Malucchi, Giovanna Borriello, Emilio Portaccio, Valentina Panetta, Giuseppe Fenu, Francesca Sangalli, Laura Cacciaguerra & Maria Trojano. (2016) Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery 13:6, pages 799-805.
Read now
Read now
Nina Parikh Thomas, Suellen Curkendall, Amanda M. Farr, Elaine Yu & Dana Hurley. (2016) The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. Journal of Medical Economics 19:5, pages 497-505.
Read now
Read now
Jing-fen Jin, Ling-ling Zhu, Meng Chen, Hui-min Xu, Hua-fen Wang, Xiu-qin Feng, Xiu-ping Zhu & Quan Zhou. (2015) The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Preference and Adherence 9, pages 923-942.
Read now
Read now
Sander Yermakov, Matthew Davis, Michaela Calnan, Monica Fay, Brieana Cox-Buckley, Sujata Sarda, Mei Sheng Duh & Ravi Iyer. (2015) Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. Journal of Medical Economics 18:9, pages 711-720.
Read now
Read now
Laura M. Hancock, Jared M. Bruce, Amanda S. Bruce & Sharon G. Lynch. (2015) Processing speed and working memory training in multiple sclerosis: A double-blind randomized controlled pilot study. Journal of Clinical and Experimental Neuropsychology 37:2, pages 113-127.
Read now
Read now
Matteo Caporro, Giulio Disanto, Claudio Gobbi & Chiara Zecca. (2014) Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment. Patient Preference and Adherence 8, pages 1123-1134.
Read now
Read now
Volker Limmroth & Kathrin Gerbershagen. (2014) Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a. Expert Opinion on Drug Delivery 11:12, pages 1969-1978.
Read now
Read now
Niklas Bergvall, Allison A. Petrilla, Swapna U. Karkare, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Charles Makin, Catherine Balderston McGuiness & Jonathan R. Korn. (2014) Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Journal of Medical Economics 17:10, pages 696-707.
Read now
Read now
Alessandra Lugaresi, Maria Rosa Rottoli & Francesco Patti. (2014) Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Review of Neurotherapeutics 14:9, pages 1029-1042.
Read now
Read now
Alessandra Lugaresi, Tjalf Ziemssen, Celia Oreja-Guevara, Delyth Thomas & Elisabetta Verdun. (2012) Improving patient–physician dialog: commentary on the results of the MS Choices survey. Patient Preference and Adherence 6, pages 143-152.
Read now
Read now
Alberto Riñon, Mandy Buch, Derek Holley & Elisabetta Verdun. (2011) The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Preference and Adherence 5, pages 629-643.
Read now
Read now
M. A. Oleen-Burkey, A. Dor, J. Castelli-Haley & M. J. Lage. (2011) The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. Journal of Medical Economics 14:6, pages 739-747.
Read now
Read now
Articles from other publishers (62)
Aleksandra Kołtuniuk, Aleksandra Pytel, Dorota Krówczyńska & Justyna Chojdak-Łukasiewicz. (2022) The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis—Cross-Sectional Study. International Journal of Environmental Research and Public Health 19:21, pages 14549.
Crossref
Crossref
Yuika Komatsu, Satoshi Yokoyama, Kouichi Hosomi & Mitsutaka Takada. (2022) Impact of Medication Adherence on the Association Between Oral Anticoagulant Use and Risk of Dementia: A Retrospective Cohort Study using the Japanese Claims Database. Drugs - Real World Outcomes 9:3, pages 437-449.
Crossref
Crossref
N. Giedraitiene, V. Taluntiene & G. Kaubrys. (2022) Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study. Scientific Reports 12:1.
Crossref
Crossref
Miranda Z. Kozlicki, Brandon Markley, Nisha B. Shah, Josh DeClercq, Leena Choi & Autumn D. Zuckerman. (2022) A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy. Multiple Sclerosis and Related Disorders 63, pages 103860.
Crossref
Crossref
Tjalf Ziemssen, Anna Kurzeja, Bogdan Muresan, Jennifer S Haas, Jessica Alexander & Maurice T Driessen. (2022) Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. Neurodegenerative Disease Management 12:2, pages 93-107.
Crossref
Crossref
Volker Limmroth, Kirsten Bayer-Gersmann, Christian Mueller & Markus Schürks. (2022) Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study. JMIR Formative Research 6:3, pages e31972.
Crossref
Crossref
Aleksandra Kołtuniuk & Justyna Chojdak-Łukasiewicz. (2022) Adherence to Therapy in Patients with Multiple Sclerosis—Review. International Journal of Environmental Research and Public Health 19:4, pages 2203.
Crossref
Crossref
Søren Krogh, Anette B. Jønsson, Per Aagaard & Helge Kasch. (2022) Efficacy of repetitive transcranial magnetic stimulation for improving lower limb function in individuals with neurological disorders: A systematic review and meta-analysis of randomized sham-controlled trials. Journal of Rehabilitation Medicine 54, pages jrm00256.
Crossref
Crossref
Oisín Butler, Simone Heeg, Katsiaryna Holl, Ann-Kathrin Frenz, Eva-Maria Wicklein, Mark Rametta & Sandy Yeo. (2021) Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT® Autoinjector: A Retrospective Cohort Study. Drugs - Real World Outcomes 8:3, pages 359-367.
Crossref
Crossref
Jared M. Bruce, Julia S. Cozart, Robin P. Shook, Stephanie Ruppen, Catherine Siengsukon, Steve Simon, Christie Befort, Sharon Lynch, Rola Mahmoud, Betty Drees, Abigail N. Norouzinia, Taylor Bradish, Paige Posson, Paul R. Hibbing & Amanda S. Bruce. (2021) Modifying Diet and Exercise in MS (MoDEMS): Study design and protocol for a telehealth weight loss intervention for adults with obesity & Multiple Sclerosis. Contemporary Clinical Trials 107, pages 106495.
Crossref
Crossref
Vanessa Marcon de Oliveira, Cinthia Caldas Rios, Vanessa Terezinha Gubert, Cristiane Munaretto Ferreira, Erica Freire de Vasconcelos-Pereira, Mônica Cristina Toffoli-Kadri & Maria Tereza Ferreira Duenhas Monreal. (2021) Association of clinical epidemiological factors to polypharmacy among patients with multiple sclerosis: real-life data. ABCS Health Sciences 46.
Crossref
Crossref
Alessandra Buja, Guendalina Graffigna, Simona F. Mafrici, Tatjana Baldovin, Carlo Pinato, Umberto Bolzonella, Serena Barello, Alessia Tognetto & Gianfranco Damiani. (2021) Adherence to Therapy, Physical and Mental Quality of Life in Patients with Multiple Sclerosis. Journal of Personalized Medicine 11:7, pages 672.
Crossref
Crossref
Adam BurkhardJoshua ToliverKaren Rascati. (2021) Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. Journal of Managed Care & Specialty Pharmacy 27:7, pages 915-923.
Crossref
Crossref
Serkan Demir, Melih Tutuncu, Cihat Uzunkopru, Haluk Gumus, Sedat Sen, Tuncay Gunduz, Ipek Gungor Dogan, Bilge Piri Cinar, Sila Usar Incirli, Mesude Tutuncu, Kamil Mavi, Suha Yuksel, Rifat Erdem Togrol, Ayse Sagduyu Kocaman & Aksel Siva. (2021) A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey. Multiple Sclerosis and Related Disorders 52, pages 103005.
Crossref
Crossref
Natalie J EngmannDanny SheinsonKomal BawaCarmen D NgGabriel Pardo. (2021) Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. Journal of Managed Care & Specialty Pharmacy 27:5, pages 639-649.
Crossref
Crossref
Wolfgang Köhler, Kirsten Bayer-Gersmann, Thomas Neußer, Markus Schürks & Tjalf Ziemssen. (2021) Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort Study. Frontiers in Neurology 12.
Crossref
Crossref
Gisela Zanga, Estefania Drzewiscki, Paula Tagliani, Maximiliano Smietniansky, Maria M. Esnaola y Rojas & Diego Caruso. (2021) Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis. Therapeutic Advances in Neurological Disorders 14, pages 175628642110310.
Crossref
Crossref
Aimee M. Banks, Megan E. Peter, Genna M. Holder, Jacob A. Jolly, Brandon M. Markley, Scott L. Zuckerman, Leena Choi, Sam Nwosu & Autumn D. Zuckerman. (2019) Adherence to Disease-Modifying Therapies at a Multiple Sclerosis Clinic: The Role of the Specialty Pharmacist. Journal of Pharmacy Practice 33:5, pages 605-611.
Crossref
Crossref
Kathiaja Miranda Souza, Isabela Maia Diniz, Lívia Lovato Pires de Lemos, Nélio Gomes Ribeiro Junior, Isabella de Figueiredo Zuppo, Juliana Alvares Teodoro, Francisco de Assis Acurcio, Álvaro Nagib Atallah & Augusto Afonso Guerra Júnior. (2020) Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. PLOS ONE 15:9, pages e0238476.
Crossref
Crossref
James M. Stankiewicz & Howard L. Weiner. (2019) An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurology - Neuroimmunology Neuroinflammation 7:1, pages e636.
Crossref
Crossref
Adel Alhazzani, Mohammed Alqahtani, Noof Alamri, Leen Sarhan, Shahad Alkhashrami & Mohammed Alahmarii. (2019) Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi Arabia. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 55:1.
Crossref
Crossref
Volker Limmroth, Klaus Hechenbichler, Christian Müller & Markus Schürks. (2019) Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp). Journal of Medical Internet Research 21:7, pages e14373.
Crossref
Crossref
Jonathan Roux, Olivier Grimaud & Emmanuelle Leray. (2018) Use of state sequence analysis for care pathway analysis: The example of multiple sclerosis. Statistical Methods in Medical Research 28:6, pages 1651-1663.
Crossref
Crossref
Marie Sanchirico, Amanda Caldwell-Tarr, Pallavi Mudumby, Lobat Hashemi & Robert Dufour. (2018) Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment. Neurology and Therapy 8:1, pages 121-133.
Crossref
Crossref
Christine Lebrun-Frenay, Antoine Moulignier, Charles Pierrot-Deseilligny, Rabah Benrabah, Thibault Moreau, Catherine Lubetzki & Françoise Monchecourt. (2019) Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France. Journal of Neurology 266:4, pages 888-901.
Crossref
Crossref
Emma Bartolomé-García, Ángela Usarralde-Pérez, Patricia Sanmartín-Fenollera & Monserrat Pérez-Encinas. (2019) Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis. European Journal of Hospital Pharmacy 26:1, pages 23-28.
Crossref
Crossref
Aliza Ben-Zacharia, Meagan Adamson, Allison Boyd, Paula Hardeman, Jennifer Smrtka, Bryan Walker & Tracy Walker. (2018) Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis. International Journal of MS Care 20:6, pages 287-297.
Crossref
Crossref
Andrew V. Thach, Carolyn M. Brown, Vivian Herrera, Rahul Sasane, Jamie C. Barner, Kentya C. Ford & Kenneth A. Lawson. (2018) Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis. International Journal of MS Care 20:6, pages 251-259.
Crossref
Crossref
Marti GroenewegSara H. ForresterBeth ArnoldLorella PalazzoWeiwei ZhuPaul YoonTim Scearce. (2018) One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program. Journal of Managed Care & Specialty Pharmacy 24:5, pages 458-463.
Crossref
Crossref
Christine Poulos, Elizabeth Kinter, Johan van Beek, Katrine Christensen & Joshua Posner. (2018) PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE. International Journal of Technology Assessment in Health Care 34:4, pages 425-433.
Crossref
Crossref
Michael Munsell, Molly Frean, Joseph Menzin & Amy L. Phillips. (2017) Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs. BMC Neurology 17:1.
Crossref
Crossref
I. N. Abdurasulova, E. I. Ermolenko, A. V. Matsulevich, K. O. Abdurasulova, E. A. Tarasova, I. V. Kudryavtsev, G. N. Bisaga, A. N. Suvorov & V. M. Klimenko. (2017) Effects of Probiotic Enterococci and Glatiramer Acetate on the Severity of Experimental Allergic Encephalomyelitis in Rats. Neuroscience and Behavioral Physiology 47:7, pages 866-876.
Crossref
Crossref
Michal Shani, Alex Lustman & Shlomo Vinker. (2017) Diabetes medication persistence, different medications have different persistence rates. Primary Care Diabetes 11:4, pages 360-364.
Crossref
Crossref
Michal Shani, Shlomo Vinker & Leonid Feldman. (2017) End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes. The Journal of Clinical Hypertension 19:6, pages 627-631.
Crossref
Crossref
Kyla A McKay, Helen Tremlett, Scott B Patten, John D Fisk, Charity Evans, Kirsten Fiest, Trudy Campbell & Ruth Ann Marrie. (2016) Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Multiple Sclerosis Journal 23:4, pages 588-596.
Crossref
Crossref
E. V. Popova, K. V. Novikova, N. V. Khachanova, O. E. Konovalova, M. Kh. Kozhieva, M. V. Davydovskaya & A. N. Boyko. (2017) The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 117:10, pages 48.
Crossref
Crossref
Lucas Higuera, Caroline S. Carlin & Sarah Anderson. (2016) Adherence to Disease-Modifying Therapies for Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 22:12, pages 1394-1401.
Crossref
Crossref
Virginia A. Devonshire, Anthony Feinstein & Patrick Moriarty. (2016) Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Research Notes 9:1.
Crossref
Crossref
Tara Nazareth, Howard S. Friedman, Prakash Navaratnam, Denise A. Herriott, John J. Ko, Peri Barr & Rahul Sasane. (2016) Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review. BMC Neurology 16:1.
Crossref
Crossref
Marcello Moccia, Raffaele Palladino, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi, Roberta Lanzillo & Vincenzo Brescia Morra. (2016) Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 10, pages 90-96.
Crossref
Crossref
Rocco Haase, Jennifer S. Kullmann & Tjalf Ziemssen. (2016) Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Therapeutic Advances in Neurological Disorders 9:4, pages 250-263.
Crossref
Crossref
Charity Evans, Ruth Ann Marrie, Feng Zhu, Stella Leung, Xinya Lu, Dessalegn Y. Melesse, Elaine Kingwell, Yinshan Zhao & Helen Tremlett. (2016) Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders 8, pages 78-85.
Crossref
Crossref
Jill R Settle, Heidi W Maloni, McKenzie Bedra, Joseph Finkelstein, Min Zhan & Mitchell T Wallin. (2015) Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study. Journal of Telemedicine and Telecare 22:4, pages 225-233.
Crossref
Crossref
Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, François Grand’Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolaños, Marcela Fiol, Eugenio Pucci, Jeannette Lechner-Scott, Freek Verheul, Edgardo Cristiano, Vincent Van Pesch, Tatjana Petkovska-Boskova, Fraser Moore, Ilya Kister, Roberto Bergamaschi, Maria Laura Saladino, Mark Slee, Michael Barnett, Maria Pia Amato, Cameron Shaw, Neil Shuey, Carolyn Young, Orla Gray, Ludwig Kappos, Helmut Butzkueven, Tomas Kalincik & Vilija Jokubaitis. (2015) The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal 22:4, pages 520-532.
Crossref
Crossref
Christine Poulos, Elizabeth Kinter, Jui-Chen Yang, John F. P. Bridges, Joshua Posner & Anthony T. Reder. (2015) Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. The Patient - Patient-Centered Outcomes Research 9:2, pages 171-180.
Crossref
Crossref
Jared Bruce, Amanda Bruce, Sharon Lynch, Lauren Strober, Sean O’Bryan, Deborah Sobotka, Joan Thelen, Abigail Ness, Morgan Glusman, Kathy Goggin, Andrea Bradley-Ewing & Delwyn Catley. (2015) A pilot study to improve adherence among MS patients who discontinue treatment against medical advice. Journal of Behavioral Medicine 39:2, pages 276-287.
Crossref
Crossref
Christine Poulos, Elizabeth Kinter, Jui-Chen Yang, John F. P. Bridges, Joshua Posner, Erika Gleißner, Axel Mühlbacher & Bernd Kieseier. (2016) A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Therapeutic Advances in Neurological Disorders 9:2, pages 95-104.
Crossref
Crossref
Zaza Katsarava, Birgit Ehlken, Volker Limmroth, Kirsi Taipale, Sarita Noemi Patel, Gabriele Niemczyk, Karin Rehberg-Weber & Colin Wernsdörfer. (2015) Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurology 15:1.
Crossref
Crossref
Cécile Donzé, Lucie Malapel, Arnaud Kwiatkowski, Bruno Lenne, Pierre Louchard, Véronique Neuville & Patrick Hautecoeur. (2015) Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE. Multiple Sclerosis Journal - Experimental, Translational and Clinical 1, pages 205521731560072.
Crossref
Crossref
Keith Tolley, Michael Hutchinson, Xiaojun You, Ping Wang, Bjoern Sperling, Ankush Taneja, Mohammed Kashif Siddiqui & Elizabeth Kinter. (2015) A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. PLOS ONE 10:6, pages e0127960.
Crossref
Crossref
Simon Zhornitsky, Jamie Greenfield, Marcus W. Koch, Scott B. Patten, Colleen Harris, Winona Wall, Katayoun Alikhani, Jodie Burton, Kevin Busche, Fiona Costello, Jeptha W. Davenport, Scott E. Jarvis, Dina Lavarato, Helene Parpal, David G. Patry, Michael Yeung & Luanne M. Metz. (2015) Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study. PLOS ONE 10:4, pages e0123824.
Crossref
Crossref
B.A. Cohen, P.K. Coyle, T. Leist, M.A. Oleen-Burkey, M. Schwartz & H. Zwibel. (2015) Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse. Multiple Sclerosis and Related Disorders 4:1, pages 75-82.
Crossref
Crossref
Georgios Hadjigeorgiou, Efthimios Dardiotis, Georgios Tsivgoulis, Triantafyllos Doskas, Damianos Petrou, Nikolaos Makris, Nikolaos Vlaikidis, Thomas Thomaidis, Athanasios Kyritsis, Nikolaos Fakas, Xoulietta Treska, Clementine Karageorgiou, Stefania Sotirli, Christos Giannoulis, Dimitra Papadimitriou, Ioannis Mylonas, Evaggelos Kouremenos, Georgios Vlachos, Dimitrios Georgiopoulos, Despoina Mademtzoglou, Michalis Vikelis & Elias Zintzaras. (2014) Observational Study Assessing Demographic, Economic and Clinical Factors Associated with Access and Utilization of Health Care Services of Patients with Multiple Sclerosis under Treatment with Interferon Beta-1b (EXTAVIA). PLoS ONE 9:11, pages e113933.
Crossref
Crossref
Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Allison A. Petrilla, Swapna U. Karkare, Catherine Balderston McGuiness & Jonathan R. Korn. (2014) Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. PLoS ONE 9:2, pages e88472.
Crossref
Crossref
Luca Prosperini, Chiara Rosa Mancinelli, Carlo Pozzilli, Maria Grazia Grasso, Alessandro Clemenzi, Sara Collorone, Simona Pontecorvo, Ada Francia, Veronica Villani, Tatiana Koudriavtseva, Fabio Buttari, Diego Centonze, Giancarlo Di Battista, Giovanni Frisullo, Simonetta Galgani & Claudio Gasperini. (2014) From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. European Neurology 71:5-6, pages 233-241.
Crossref
Crossref
Robert J. Fox, Amber R. Salter, Tuula Tyry, Jennifer Sun, Xiaojun You, Genevieve Laforet & Denise Campagnolo. (2013) Treatment Discontinuation and Disease Progression with Injectable Disease-Modifying Therapies. International Journal of MS Care 15:4, pages 194-201.
Crossref
Crossref
Ana Ožura, Lea Kovač & Saša Šega. (2013) Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis. Clinical Neurology and Neurosurgery 115, pages S6-S11.
Crossref
Crossref
F. Santoleri, P. Sorice, R. Lasala, C. D’Amario & A. Costantini. (2013) RDD e PDD: strumenti per l’aderenza e la persistenza nelle analisi di farmacoutilizzazione: il caso degli analoghi della somatostatina (2007–2011)RDD and PDD: tools to evaluate adherence and persistence in drug utilization studies. The case of somatostatin analogs (2007–2011). PharmacoEconomics Italian Research Articles 15:2, pages 75-82.
Crossref
Crossref
Alessandra Lugaresi, Ciro Florio, Vincenzo Brescia-Morra, Salvatore Cottone, Paolo Bellantonio, Marinella Clerico, Diego Centonze, Antonio Uccelli, Maria di Ioia, Giovanna De Luca, Andrea Marcellusi & Andrea Paolillo. (2012) Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurology 12:1.
Crossref
Crossref
Aaron E. Miller & Robert W. Rhoades. (2012) Treatment of relapsing-remitting multiple sclerosis. Current Opinion in Neurology 25, pages S4-S10.
Crossref
Crossref
Charity Evans, Jennifer Tam, Elaine Kingwell, Joel Oger & Helen Tremlett. (2012) Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study. Clinical Therapeutics 34:2, pages 341-350.
Crossref
Crossref
Rachel Halpern, Sonalee Agarwal, Leigh Borton, Kathy Oneacre & Maria V. Lopez-Bresnahan. (2011) Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis. Advances in Therapy 28:9, pages 761-775.
Crossref
Crossref